Schuurhuis GJ - Search Results

1

IMGN779, a Novel CD33-Targeting Antibody-Drug Conjugate with DNA-Alkylating Activity, Exhibits Potent Antitumor Activity in Models of AML.

Kovtun Y, Noordhuis P, Whiteman KR, Watkins K, Jones GE, Harvey L, Lai KC, Portwood S, Adams S, Sloss CM, Schuurhuis GJ, Ossenkoppele G, Wang ES, Pinkas J. Kovtun Y, et al. Among authors: schuurhuis gj. Mol Cancer Ther. 2018 Jun;17(6):1271-1279. doi: 10.1158/1535-7163.MCT-17-1077. Epub 2018 Mar 27. Mol Cancer Ther. 2018. PMID: 29588393

2

MRD in AML: time for redefinition of CR?

Ossenkoppele G, Schuurhuis GJ. Ossenkoppele G, et al. Among authors: schuurhuis gj. Blood. 2013 Mar 21;121(12):2166-8. doi: 10.1182/blood-2013-01-480590. Blood. 2013. PMID: 23520326 Free article. No abstract available.

3

Attenuation of microRNA-126 expression that drives CD34+38- stem/progenitor cells in acute myeloid leukemia leads to tumor eradication.

de Leeuw DC, Denkers F, Olthof MC, Rutten AP, Pouwels W, Schuurhuis GJ, Ossenkoppele GJ, Smit L. de Leeuw DC, et al. Among authors: schuurhuis gj. Cancer Res. 2014 Apr 1;74(7):2094-105. doi: 10.1158/0008-5472.CAN-13-1733. Epub 2014 Jan 29. Cancer Res. 2014. PMID: 24477595

4

MRD in AML: it is time to change the definition of remission.

Ossenkoppele GJ, Schuurhuis GJ. Ossenkoppele GJ, et al. Among authors: schuurhuis gj. Best Pract Res Clin Haematol. 2014 Sep-Dec;27(3-4):265-71. doi: 10.1016/j.beha.2014.10.008. Epub 2014 Oct 15. Best Pract Res Clin Haematol. 2014. PMID: 25455276 Review.

5

MRD in AML: does it already guide therapy decision-making?

Ossenkoppele G, Schuurhuis GJ. Ossenkoppele G, et al. Among authors: schuurhuis gj. Hematology Am Soc Hematol Educ Program. 2016 Dec 2;2016(1):356-365. doi: 10.1182/asheducation-2016.1.356. Hematology Am Soc Hematol Educ Program. 2016. PMID: 27913502 Free PMC article. Review.

6

Quantification of T-cell-mediated apoptosis in heterogeneous leukemia populations using four-color multiparameter flow cytometry.

Westers TM, Houtenbos I, Schuurhuis GJ, Ossenkoppele GJ, van de Loosdrecht AA. Westers TM, et al. Among authors: schuurhuis gj. Cytometry A. 2005 Jul;66(1):71-7. doi: 10.1002/cyto.a.20146. Cytometry A. 2005. PMID: 15895438 Free article.

7

New approaches for the detection of minimal residual disease in acute myeloid leukemia.

van Rhenen A, Moshaver B, Ossenkoppele GJ, Schuurhuis GJ. van Rhenen A, et al. Among authors: schuurhuis gj. Curr Hematol Malig Rep. 2007 May;2(2):111-8. doi: 10.1007/s11899-007-0016-0. Curr Hematol Malig Rep. 2007. PMID: 20425359 Review.

8

Review of the relevance of aberrant antigen expression by flow cytometry in myeloid neoplasms.

Ossenkoppele GJ, van de Loosdrecht AA, Schuurhuis GJ. Ossenkoppele GJ, et al. Among authors: schuurhuis gj. Br J Haematol. 2011 May;153(4):421-36. doi: 10.1111/j.1365-2141.2011.08595.x. Epub 2011 Mar 9. Br J Haematol. 2011. PMID: 21385170 Free article. Review.

9

Purging of peripheral blood stem cell transplants in AML: a predictive model based on minimal residual disease burden.

Feller N, Jansen-van der Weide MC, van der Pol MA, Westra GA, Ossenkoppele GJ, Schuurhuis GJ. Feller N, et al. Among authors: schuurhuis gj. Exp Hematol. 2005 Jan;33(1):120-30. doi: 10.1016/j.exphem.2004.10.007. Exp Hematol. 2005. PMID: 15661405 Free article. Clinical Trial.

10

Chemotherapeutic treatment of bone marrow stromal cells strongly affects their protective effect on acute myeloid leukemia cell survival.

Moshaver B, van der Pol MA, Westra AH, Ossenkoppele GJ, Zweegman S, Schuurhuis GJ. Moshaver B, et al. Among authors: schuurhuis gj. Leuk Lymphoma. 2008 Jan;49(1):134-48. doi: 10.1080/10428190701593636. Leuk Lymphoma. 2008. PMID: 17926185

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

175 results

Search Page